JAK2 and acquired polycythemia vera: Ruxolitinib is a JAK2 inhibitor approved for the treatment of PV in adult patients with intolerance or resistance to hydroxyurea treatment, regardless of JAK2 V617F mutational status, with well-known efficacy for splenomegaly, potentially reduction of vascular events, and complete molecular remission [18].